新しい技術により胚の包括的遺伝子検査が可能に(New technique allows comprehensive genetic testing of embryos)

ad

2024-09-02 カロリンスカ研究所(KI)

カロリンスカ研究所とマーストリヒト大学の研究者が、胚を一つのテストで全ての既知の遺伝的異常を調べる技術を開発しました。この新技術は従来の方法よりも正確で迅速であり、遺伝性疾患のリスクが高い親にとって健康な子どもを持つ可能性を高めます。このテストは、全ての遺伝情報を解析し、遺伝性疾患の検出をより効率的に行うことができます。倫理的な問題も存在しますが、新技術は着床手続きを減少させる可能性があります。

<関連情報>

臨床レベルの全ゲノムシークエンシングに基づくハプラリシスにより、あらゆる形態の着床前遺伝学的検査が可能になる Clinical-grade whole genome sequencing-based haplarithmisis enables all forms of preimplantation genetic testing

Anouk E. J. Janssen,Rebekka M. Koeck,Rick Essers,Ping Cao,Wanwisa van Dijk,Marion Drüsedau,Jeroen Meekels,Burcu Yaldiz,Maartje van de Vorst,Bart de Koning,Debby M. E. I. Hellebrekers,Servi J. C. Stevens,Su Ming Sun,Malou Heijligers,Sonja A. de Munnik,Chris M. J. van Uum,Jelle Achten,Lars Hamers,Marjan Naghdi,Lisenka E. L. M. Vissers,Ron J. T. van Golde,Guido de Wert,Jos C. F. M. Dreesen,Christine de Die-Smulders,… Masoud Zamani Esteki
Nature  Communications   Published:02 September 2024
DOI:https://doi.org/10.1038/s41467-024-51508-1

新しい技術により胚の包括的遺伝子検査が可能に(New technique allows comprehensive genetic testing of embryos)

Abstract

High-throughput sequencing technologies have increasingly led to discovery of disease-causing genetic variants, primarily in postnatal multi-cell DNA samples. However, applying these technologies to preimplantation genetic testing (PGT) in nuclear or mitochondrial DNA from single or few-cells biopsied from in vitro fertilised (IVF) embryos is challenging. PGT aims to select IVF embryos without genetic abnormalities. Although genotyping-by-sequencing (GBS)-based haplotyping methods enabled PGT for monogenic disorders (PGT-M), structural rearrangements (PGT-SR), and aneuploidies (PGT-A), they are labour intensive, only partially cover the genome and are troublesome for difficult loci and consanguineous couples. Here, we devise a simple, scalable and universal whole genome sequencing haplarithmisis-based approach enabling all forms of PGT in a single assay. In a comparison to state-of-the-art GBS-based PGT for nuclear DNA, shallow sequencing-based PGT, and PCR-based PGT for mitochondrial DNA, our approach alleviates technical limitations by decreasing whole genome amplification artifacts by 68.4%, increasing breadth of coverage by at least 4-fold, and reducing wet-lab turn-around-time by ~2.5-fold. Importantly, this method enables trio-based PGT-A for aneuploidy origin, an approach we coin PGT-AO, detects translocation breakpoints, and nuclear and mitochondrial single nucleotide variants and indels in base-resolution.

細胞遺伝子工学
ad
ad
Follow
ad
タイトルとURLをコピーしました